Heart Transplantation for Hepatitis C Virus Non-Viremic Recipients From Hepatitis C Virus Viremic Donors

Authors

Shalom Z. Frager, New York Medical College
Abhay Dhand, New York Medical CollegeFollow
Alan Gass, New York Medical CollegeFollow
Avi Levine
David Spielvogel, New York Medical CollegeFollow
Rajat Nog, New York Medical CollegeFollow
David C. Wolf, New York Medical CollegeFollow
Roxana I. Bodin, New York Medical CollegeFollow

Journal Title

Cardiology in Review

First Page

179

Last Page

181

Document Type

Article

Publication Date

July 2019

Department

Medicine

Abstract

Multiple strategies have been implemented to increase the donor pool to avoid transplant wait-list mortality. The approval of highly effective direct-acting antiviral regimens for the treatment of hepatitis C virus (HCV) has enabled expansion of the donor pool by allowing the transplantation of organs from HCV-viremic donors to HCV-negative recipients. Multiple centers have recently published data on outcomes of heart transplantation from HCV-viremic heart donors to HCV-negative recipients, with acceptable posttransplant outcomes. However, areas of uncertainty remain, particularly in the long-term risks of intentional HCV transmission, as well as the possibility that sustained virologic response may not be achieved. In this article, we review the literature illustrating both the risks and benefits of transplantation of organs from HCV-viremic donors to HCV-negative recipients. We also present the data collected at our institution regarding this special patient population.

Recommended Citation

Frager, S. Z., Dhand, A., Gass, A., Levine, A., Spielvogel, D., Nog, R., Wolf, D., & Bodin, R. (2019). Heart Transplantation for Hepatitis C Virus Non-Viremic Recipients From Hepatitis C Virus Viremic Donors. Cardiology in Review, 27 (4), 179-181. https://doi.org/10.1097/CRD.0000000000000255